Jump to content

DLX-2270

Add links
From Wikipedia, the free encyclopedia

DLX-2270
Clinical data
Other namesDLX2270
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2A receptor antagonist; Serotonin 5-HT2C receptor agonist; Antipsychotic; Psychoplastogen[1]
ATC code
  • None

DLX-2270 is an experimental serotonin receptor modulator which is under investigation for the potential treatment of schizophrenia.[1][2][3]

It acts as a serotonin 5-HT2A receptor antagonist and serotonin 5-HT2C receptor agonist.[1][3] In contrast to conventional antipsychotics, DLX-2270 is not a dopamine D2 receptor antagonist.[1] The drug is orally active and centrally penetrant.[1] In preclinical research, DLX-2270 has psychoplastogenic effects.[1][3] It reverses hyperlocomotion and social interaction deficits induced by the NMDA receptor antagonist phencyclidine (PCP).[1] In contrast to serotonin 5-HT2A receptor agonists, DLX-2270 does not produce the head-twitch response in rodents, and hence would not be expected to be hallucinogenic in humans.[1][3]

DLX-0002700.[4]

DLX-2270 was first described in the scientific literature in 2025.[1] It is under development by Delix Therapeutics.[1] The drug has reached the preclinical research stage of development.[2] DLX-2270 is a small molecule, but its chemical structure does not yet appear to have been disclosed.[1] However, Delix Therapeutics has patented dual serotonin 5-HT2A receptor antagonists and serotonin 5-HT2C receptor agonists with psychoplastogenic effects for treatment of psychotic disorders, such as the cyclized isotryptamine and partial ergoline-like DLX-0002700.[4]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k l Leach P, Prince R, Agrawal R, Gillie D, Mungenast A, McTighe S, et al. (2025). "569. Preclinical Pharmacology of DLX-2270: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Schizophrenia". Biological Psychiatry. 97 (9): S333. doi:10.1016/j.biopsych.2025.02.808. Retrieved 13 May 2025.
  2. ^ a b "Delving into the Latest Updates on DLX-2270 with Synapse". Synapse. 24 January 2026. Retrieved 1 April 2026.
  3. ^ a b c d Martínez SL (27 January 2026). "The Perils of Non-Hallucinogenic Claims: On the Limits of Translatability". OPEN Foundation. Non-Hallucinogenic Labeling and Semantic Drifts: In parallel, the label "non-hallucinogenic agonist" has often been applied in an unnecessary and overly expansive manner. For example, DLX-2270 has been described as a "non-hallucinogenic neuroplastogen" despite functioning pharmacologically as a 5-HT2A receptor antagonist with concurrent 5-HT2C agonism. This mechanism is fundamentally distinct from that of a 5-HT2A agonist and illustrates the degree to which semantic drift and marketing pressures have shaped the space.
  4. ^ a b "Mixed serotonin receptor binders for treatment of psychotic disorders". Google Patents. 20 December 2024. Retrieved 1 April 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=DLX-2270&oldid=1347691817"